Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

December 23rd 2019

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Dr. Crafton on the Impact of PARP Inhibitors in Recurrent Ovarian Cancer

December 21st 2019

Sarah Crafton, MD, discusses the impact of PARP inhibitors on patients with recurrent ovarian cancer.

Dr. O'Malley on Ongoing Clinical Trials Evaluating Immunotherapy in Ovarian Cancer

December 19th 2019

David O’Malley, MD, discusses ongoing clinical trials evaluating immunotherapy in patients with advanced ovarian cancer.

Dr. Cosgrove on Retreatment With PARP Inhibitors in Ovarian Cancer

December 18th 2019

Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.

The Dividing Line for Germline Mutation Testing Is Often Arbitrary

December 18th 2019

Although hereditary cancer risk was defined solely by family history in the not-so-distant past, today increasingly robust data may help define an individual’s heightened lifetime risk based on the presence of specific molecular findings within the germline

Dr. Hays on Combining PARP Inhibitors With Immunotherapy in Ovarian Cancer

December 16th 2019

John Hays, MD, PhD, discusses investigational combinations of PARP inhibitors and immunotherapy in ovarian cancer.

More Research Must Focus on Later-Line Therapies in Ovarian Cancer

December 16th 2019

Casey M. Cosgrove, MD, discusses later-line treatments in ovarian cancer and ongoing research.

Dr. Fowler on Types of Surgical Procedures in Ovarian Cancer

December 12th 2019

Jeffrey M. Fowler, MD, discusses the various types of surgical procedures in ovarian cancer.

Olaparib Approved in China for Frontline Maintenance in Ovarian Cancer

December 5th 2019

China’s National Medical Products Administration has granted marketing authorization for olaparib as a first-line maintenance treatment for adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.

Dr. Crafton on Secondary Surgical Cytoreduction in Ovarian Cancer

December 4th 2019

Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses secondary surgical cytoreduction in recurrent ovarian cancer.

UK Expands Olaparib Maintenance Indication in Ovarian Cancer

December 3rd 2019

The UK’s National Institute for Health and Care Excellence has approved olaparib for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations.

Recent Data Muddle Role of Secondary Surgery in Recurrent Ovarian Cancer

December 3rd 2019

Sarah Crafton, MD, discusses the role of secondary surgical cytoreduction in recurrent ovarian cancer.

Dr. Crafton on Optimizing Treatment Selection in Recurrent Ovarian Cancer

November 28th 2019

Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses optimizing treatment selection in recurrent ovarian cancer.

Dr. Salani Discusses Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in Ovarian Cancer

November 22nd 2019

Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.

Combos Could Unlock Major Immunotherapy Benefits in Ovarian Cancer

November 22nd 2019

John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.

Expert Shares Insight on Evolution of Ovarian Cancer Therapeutics

November 21st 2019

Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.

Dr. Copeland on the Etiology of Ovarian Cancer

November 21st 2019

Larry J. Copeland, MD, discusses the etiology of ovarian cancer.

Individualized Approach Imperative in Frontline Ovarian Cancer

November 20th 2019

Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.

O'Malley Highlights Pivotal Trials in Ovarian Cancer

November 19th 2019

David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.

Genetic Testing Is Suggested First Step Upon Ovarian Cancer Diagnosis

November 18th 2019

Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.